

MAR 25 2002

MAR 22 2002

Please type a plus sign (+) inside this box → PTO-SB-21 (08-00)  
Approved for use through 10/31/2002, OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/737,687
Filing Date	12/14/00
First Named Inventor	Allen, Darin Arthur
Group Art Unit	1626
Examiner Name	Wright, Sonya N.
Attorney Docket Number	218

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Supplemental IDS under 37 CFR Sect.1.97 & Sect. 1.98
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Axys Pharmaceuticals, Inc. Rekha Bansal (Reg. No. 36,440)
Signature	
Date	3/22/02

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 

Typed or printed name	EVELYN NEWTON
Signature	
Date	3/22/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents  
Washington, DC 20231

Axys Pharmaceuticals, Inc.

By Ellyn Kress

**PATENT**  
Attorney Docket No: 218

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Darin Arthur Allen, et al.

Application No.: 09/737,687

Filed: December 14, 2000

For: SALICYLAMIDES AS SERINE  
PROTEASE INHIBITORS

Examiner: Sonya N. Wright

Art Unit: 1626

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR § 1.97 AND § 1.98**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. These references were cited in the International Preliminary Examination Report (PCT Rule 71.1) in a corresponding PCT application. Enclosed are copies of the Notification of Transmittal of the International Preliminary Examination Report (PCT Rule 71.1) and a copy of the International Preliminary Examination Report (PCT Article 36 and Rule 70) along with copies of the cited references. It is respectfully requested that the cited references be expressly considered during the prosecution of this

application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required because the Supplemental Information Disclosure Statement is being submitted within three months of the mailing of the Notification of Transmittal of the International Preliminary Examination Report (PCT Rule 71.1) and the International Preliminary Examination Report (PCT Article 36 and Rule 70) mailed from the International Preliminary Examining Authority on February 22, 2002. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0848. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Rekha Bansal  
Reg. No. 36,440

AXYS PHARMACEUTICALS, INC.  
180 Kimball Way  
South San Francisco, CA 94080  
Tel: 650-829-1000  
Fax: 650-866-6651